Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
28 May 2024 | Story Anthony Mthembu | Photo Jon Vincent
Ibali
Educators, academics, and policymakers in attendance at the Ibali Education Stakeholders Forum.

The Centre for Development Support (CDS) at the University of the Free State (UFS), in collaboration with Ibali, hosted the Ibali Education Stakeholders Forum on 10 May 2024 at the Centenary Complex on the UFS Bloemfontein Campus. 

According to Prof Faith Mkwananzi, Associate Professor at the CDS, the event, an initiative of the Ibali Project, aimed to ‘’inform and disseminate project findings to individuals with an interest in educational exclusion and inclusion. It also served as a forum for stakeholders to share insights on the matter. “ The forum was well attended by educators, school leaders, academics, and policymakers from the Free State. Additionally, the event saw representation from Ibali, including Dr Alison Buckler, Deputy Director of the Centre for the Study of Global Development (CSGD) at The Open University.

A platform for engagement

Discussions at the forum focused on creating inclusive learning environments for learners and students within the province and beyond. Stakeholders had the opportunity to discuss the challenges they face in fostering inclusive learning spaces through panel discussions and presentations. ’’The involvement of stakeholders and presentation of diverse perspectives contributed to a robust engagement, indicating that individuals and organisations are motivated to support an inclusive and sustainable education system at every level in South Africa,’’ said Prof Mkwananzi.

The Ibali initiative

Dr Buckler explained that Ibali is a network of researchers, practitioners, and educators interested in how storytelling can support different understandings around complex issues in education and development. One of Ibali’s projects, funded by the United Kingdom Arts and Humanities Research Council (AHRC), explores what inclusion and exclusion look like within education in countries like Nigeria, South Africa, and the United Kingdom.

Insights from the engagement

Dr Buckler highlighted several insights from the forum. She noted that inclusive practice can manifest in various ways. ‘’People talked about mixing groups of students in lectures, creating a supportive community for their deaf sibling, mainstream schools inviting children from ‘special schools’ for play sessions, and so on,’’ she said. Moreover, she emphasised that a key takeaway is that “underpinning hugely diverse examples of inclusive practice are a fairly small number of key principles around empathy, communication, ubuntu, and seeing someone as whole instead of defining people by certain characteristics that align with inclusion policies.”

As the engagement session concluded, both Prof Mkwananzi and Dr Buckler expressed hope that stakeholders could learn from one another’s experiences, fostering a more inclusive educational environment.  

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept